Jazz Pharma's decision to revoke U.S. patent for rival narcolepsy drug

Published Date: 02 Mar 2023

A U.S. court on Friday ordered Jazz Pharmaceuticals to revoke its patents related to its flagship narcolepsy drug Xyrem from the FDA-approved brand name drug after winning a case against Avadel foe CNS Pharmaceuticals.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Five new papers highlight cancer inequities, challenges and opportunities in South Asia

2.

Prostate cancer screening program beneficial in top decile of polygenic risk score

3.

How a new light-based cancer treatment could destroy tumors without harming healthy cells—using LEDs

4.

Ineffective medication can remove the "worst fear" of schizophrenia.

5.

Aspirin for CRC Risk Reduction May Benefit Unhealthy People Most


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot